Paras Sharma

@paras_biotech

In life science venture capital

Toronto, Canada

Joined June 2010

121Following

15KFollowers

Paras Sharma@paras_biotech · Jul 12

Obesity riches are fueling venture bets — Lilly and Novo are charging into Series A deals [2025 YTD]

107

14.0K

Paras Sharma@paras_biotech · Jul 12

Breaking the Billion: Blockbuster Trajectories For Drug Revenues Below is the timeline for revenue-milestone-spread for various blockbuster Oncology drugs. Source: Wells Fargo

paras_biotech's tweet image. Breaking the Billion: Blockbuster Trajectories For Drug Revenues

Below is the timeline for revenue-milestone-spread for various blockbuster Oncology drugs.

Source: Wells Fargo

112

13.0K

Paras Sharma@paras_biotech · Jul 12

Cowen: "Sentiment toward biotech stocks improved through the month of June and enters H2 above the nadir reached earlier in the Spring. Investors remain unenthusiastic, but are not nearly as despondent as they had been"

paras_biotech's tweet image. Cowen: "Sentiment toward biotech stocks improved through the month of June and enters H2 above the nadir reached earlier in the Spring. Investors remain unenthusiastic, but are not nearly as despondent as they had been"

22.0K

Paras Sharma@paras_biotech · Jul 12

Fund flows for $XBI stands YTD net outflows $1,230M **YTD Pharma is performing below the S&P but above other healthcare metrics we track: Pharma is up +3.5%, XBI is down -5.4%, and Large-Cap Biotech stocks are up +0.8%, compared to the S&P 500, up +6.8%. Source: Needham

paras_biotech's tweet image. Fund flows for $XBI stands YTD net outflows $1,230M

**YTD Pharma is performing below the S&amp;P but above other healthcare metrics we track: Pharma is up +3.5%, XBI is down -5.4%, and Large-Cap Biotech stocks are up +0.8%, compared to the S&amp;P 500, up +6.8%.

Source: Needham

3.0K

Paras Sharma@paras_biotech · Jul 5

2014-2025 Biotech Valuations: The decline in private biotech valuations signals a structural, not just cyclical, shift—driven by a reassessment of risk tolerance, expected returns, and capital efficiency

paras_biotech's tweet image. 2014-2025 Biotech Valuations:

The decline in private biotech valuations signals a structural, not just cyclical, shift—driven by a reassessment of risk tolerance, expected returns, and capital efficiency

13.0K

Paras Sharma@paras_biotech · Jul 5

Therapeutic and strategic analysis of biopharma companies trading below cash: 60/106 negative EV companies with mc <$100M, compared to 7 companies with a market cap above $500M 39% of these companies were oncology-focused; over half were in either Ph I or II Source: Canaccord

paras_biotech's tweet image. Therapeutic and strategic analysis of biopharma companies trading below cash:

60/106 negative EV companies with mc &lt;$100M, compared to 7 companies with a market cap above $500M

39% of these companies were oncology-focused; over half were in either Ph I or II

Source: Canaccord

148

168

31.0K

Paras Sharma@paras_biotech · Jul 5

2014-2025: Venture financings across various stages of Biotechs - Historically, pre-clinical/clinical biotech were equally funded - Investors in 2020/21 peak went all in preclinical unproven/conceptual biotech - However, in '24 Preclinical biotechs felt the most pain

paras_biotech's tweet image. 2014-2025: Venture financings across various stages of Biotechs

- Historically, pre-clinical/clinical biotech were equally funded
- Investors in 2020/21 peak went all in preclinical unproven/conceptual biotech
- However, in '24 Preclinical biotechs felt the most pain

10.0K

Paras Sharma@paras_biotech · Jun 28

Centerview: advised on 38 of the 48 $1bn+ deals since 2023

188

128

41.0K

Paras Sharma@paras_biotech · Jun 22

Cowen's biotech thermometer: "Biotech seems to be at the center of the political storm, buffeted from all directions by initiatives that have the potential to meaningfully change the way biopharmaceuticals are licensed, reimbursed, or manufactured"

paras_biotech's tweet image. Cowen's biotech thermometer: "Biotech seems to be at the center of the political storm, buffeted from all directions by initiatives that have the potential to meaningfully change the way biopharmaceuticals are licensed, reimbursed, or manufactured"

15.0K

Paras Sharma@paras_biotech · Jun 22

RBC's shortlist of CDER potential Director candidates

4.0K

Paras Sharma@paras_biotech · May 25

"In the past two months, more than a dozen of the largest multi national biopharma co's have announced plans to invest ~$280B in US" Source: Wells Fargo

paras_biotech's tweet image. "In the past two months, more than a dozen of the largest multi national biopharma co's have announced plans to invest ~$280B in US"

Source: Wells Fargo

19.0K

Paras Sharma@paras_biotech · May 11

Who got the boot at the FDA:

17.0K